A study showed Moderna’s vaccine produced more than twice the antibodies of Pfizer.
A study comparing the Covid vaccines of Pfizer (PFE) – Get Pfizer Inc. Report/BioNTech (BNTX) – Get BioNTech SE Sponsored ADR Report and Moderna (MRNA) – Get Moderna, Inc. Report showed that Moderna’s produced more than twice the antibodies of Pfizer/BioNTech’s.
The trial included 2,499 Belgian health-care workers who were vaccinated with two doses of either vaccine. It was published Monday in the Journal of the American Medical Association.
At last check Moderna shares rose 2.7% to $380.81; Pfizer traded at $46.79, little changed; and BioNTech was at $343.77, off 0.3%.
“Higher antibody titers were observed in participants vaccinated with 2 doses of mRNA-1273 [the Moderna vaccine] compared with those vaccinated with BNT162b2 [the Pfizer/BioNTech] vaccine,” the JAMA article read.
“Previously infected participants had higher antibody titers compared with previously uninfected participants.”
Further, “Antibody levels negatively correlated with age in previously uninfected participants, being highest among those younger than 35 years,” the article said.
“Across all age categories, previously uninfected participants vaccinated with mRNA-1273 had higher antibody titers compared with those vaccinated with BNT162b2.”
So why did Moderna outperform?
“The higher mRNA content in mRNA-1273 compared with BNT162b2 and the longer interval between priming and boosting for mRNA-12733 (four weeks versus three weeks for BNT162b2) might explain this difference,” the article said.
On Thursday, TheStreet.com detailed how various companies are approaching the issue of vaccines for their workers.
At Goldman Sachs (GS) – Get Goldman Sachs Group, Inc. (GS) Report, starting Sept. 7 the New York investment bank will require staff, clients, and visitors to show their vaccination cards while entering its U.S. offices.